WHO counts 695 confirmed Bundibugyo Ebola cases and 138 deaths, up 30 percent in five days across 29 health zones. Contact tracing has jumped past 70 percent, but only 46 percent of confirmed patients are isolated, and isolation is the number the CDC model says decides the outbreak. A treatment trial has finally gone live.
Bundibugyo fixed its financing gap but not its isolation bottleneck, and security access controls both.
WHO Disease Outbreak News 607 logged 695 confirmed Bundibugyo Ebola cases and 138 deaths across DRC and Uganda on 13 June, a 30 percent rise in five days. Contact tracing has surged past 70 percent; patient isolation has not.
WHO's 13 June Disease Outbreak News counted 695 confirmed Bundibugyo Ebola cases and 138 deaths across DRC and Uganda, up 30 percent in five days. Contact tracing exceeded 70 percent across all three affected provinces in DRC.
Only 46 percent of confirmed patients were in isolation as of 14 June, against the CDC model's 70 percent threshold where worst-case trajectory collapses. That gap between tracing and isolation is where the outbreak's next month will be decided.
DRC's health ministry counted 782 confirmed cases on 14 June with 359 patients isolated, a 45.9 percent rate. The CDC model says 70 percent isolation collapses the worst case; 46 percent leaves it open.
DRC's national health ministry counted 782 confirmed cases on 14 June, with 359 patients in isolation, 45.9 percent of the confirmed total. The CDC model, which puts the reproduction number at 2.51, identifies 70 percent isolation as the threshold where the August worst case falls from 65 percent to 1 percent.
At 45.9 percent, the response sits between the model's floor and its collapse threshold. Closing that gap depends on security access to treatment units, which tracing alone cannot deliver.
A clinical trial of MBP134 plus Regeneron's REGN3479, with obeldesivir for those exposed, is now underway, the first authorised therapeutic intervention in an outbreak that ran for weeks with nothing to dose.
A clinical trial of three experimental medicines for Bundibugyo Ebola began as of 13 June in DRC and Uganda. It tests MBP134 plus REGN3479 as treatment, and obeldesivir as a preventive drug for people WHO have been exposed but are not yet ill.
This is the first authorised therapeutic intervention in an outbreak that ran for weeks with no treatment to offer. DRC and Uganda lead the trial design, with community consultation and ethics review still pending.
The 30-day US entry ban on DRC, Uganda and South Sudan nationals, widened to green-card holders on 5 June, expires around 17 June with no announced lift. Africa CDC calls it of 'little, if any, benefit'.
A 30-day US entry ban on nationals of DRC, Uganda and South Sudan, expanded on 5 June to include green-card holders, reached its expiry around 17 June with no announced extension or lift. The Africa CDC Emergency Consultative Group called the restriction of 'little, if any, benefit'.
The US simultaneously funds $270 million of the outbreak response it is restricting travel from. The scientific record on entry bans shows they delay rather than prevent importation and reduce surveillance cooperation.
Africa CDC counted 34 infected healthcare workers as of 10 June. Four nurses treated at Bunia hospital recovered and were discharged, the first named recoveries from a DRC facility this outbreak.
Africa CDC's Advisory and Technical Council reported 34 healthcare workers infected as of 10 June, the first aggregate count since four deaths at Mongbwalu Hospital in May. Four nurses recovered and were discharged from Bunia hospital in Ituri, the first named Ebola survivors from a DRC treatment facility in this outbreak.
Thirty-four infections, about 4.5 percent of confirmed cases, exceed the two percent threshold public health agencies use to flag infection-prevention failures.
The Pandemic Fund activated up to 220.6 million dollars on 5 June; the US State Department committed 270 million bilaterally. Set against May's summit pledges, the mobilised aggregate approaches 990 million dollars.
The Pandemic Fund activated up to $220.6 million in emergency grants on 5 June, and the US State Department committed $270 million bilaterally. Combined with pledges at the Africa CDC summit in May, the total response funding approaches $990 million.
The Pandemic Fund's own statement names the paradox: no vaccine, no approved treatment, and no rapid diagnostic test exist for this virus. Nearly a billion dollars cannot buy a licensed medical countermeasure that has not yet been developed.
CEPI awarded Public Health Vaccines LLC 1.9 million dollars on 9 June for a fourth Bundibugyo candidate, bringing the portfolio to four across three platforms. Africa CDC still flags the missing bedside test.
CEPI awarded Public Health Vaccines LLC $1.9 million on 9 June to generate starter viral seed stock for a fourth Bundibugyo vaccine candidate, using the rVSV biological platform. The total Bundibugyo vaccine portfolio across four candidates now stands at roughly $63.7 million.
None of these vaccines will be ready during the current outbreak. Africa CDC also flagged that no rapid bedside test for Bundibugyo Ebola exists; every case still requires a PCR laboratory assay for confirmation.
Kerala confirmed a Nipah case in Kozhikode on 11 June, a 43-year-old man critical on a ventilator after cleaning a bat-infested building. ICMR traced about 100 contacts, 58 of them healthcare workers.
Kerala confirmed a Nipah virus case in a 43-year-old man in Kozhikode on 11 June after he cleaned a bat-roosting building. The Indian Council of Medical Research deployed a team and traced roughly 100 contacts, including 58 healthcare workers. Three consecutive days with no new cases followed.
Nipah kills 40 to 75 percent of those it infects and has no licensed vaccine. Kerala has contained every spillover event since 2018 using a standing rapid-response protocol developed after the first outbreak.
Two papers in Emerging Infectious Diseases document suspected sexual transmission of Dermatophilus congolensis, a cattle skin bacterium, among men who have sex with men in Barcelona, Lyon and Paris. ECDC reports on 23 June.
Two peer-reviewed papers in June's Emerging Infectious Diseases document Dermatophilus congolensis, a livestock bacterium, spreading sexually among men WHO have sex with men in Barcelona, Lyon and Paris from December 2025 to March 2026. Nine Barcelona cases had genomes 0 to 4 single-nucleotide differences apart, pointing to one human-transmitting lineage.
All cases were mild and cleared with standard antibiotics. The ECDC is assessing whether this represents sustained human-to-human spread or a detection-sensitive cluster; its finding is due 23 June.
Mpox clade Ib is circulating locally among men who have sex with men in Europe with no Africa travel history, the first confirmed local clade I transmission on the continent. All 23 US cases stay travel-linked.
Mpox clade Ib is spreading locally in Europe among men WHO have sex with men with no Africa travel history, the first local clade I transmission on the continent. All 23 US clade I cases remain travel-linked.
The CDC expects US case numbers to rise as the FIFA World Cup drives international movement. Clade Ib and the Dermatophilus bacterium cases reported the same week are independent pathogens with no link between them.
The Americas logged 20,521 measles cases in the first five months of 2026, with Mexico alone at 10,920, weeks before it co-hosts the FIFA World Cup and draws crowds into an unvaccinated cohort.
Mexico reported 10,920 measles cases this year, the highest burden in the Americas, as it prepares to co-host the FIFA World Cup from mid-June. The Americas total reached 20,521 cases over the same months.
The cases concentrate in children and young adults WHO missed routine MMR shots during the pandemic. Mass-gathering events with mixed international vaccination histories are the classic amplifier for resurgent measles, and no catch-up campaign for World Cup host cities has been publicly announced.
Escalating in case count, indeterminate on trajectory. DRC confirmed cases rising above 20 per day across 29 health zones, with isolation at 45.9 percent rising but still 24 percentage points below the CDC model's collapse threshold. The decisive inflection will be a sustained isolation rate above 60 percent, which requires either security improvements in conflict-affected zones or acceleration of treatment unit construction in accessible areas. Uganda's urban cluster at 19 cases with onward transmission in Kampala tests whether the 2022 Sudan ebolavirus playbook holds for a second Ebola species in a dense capital.
